Literature DB >> 24554412

CGB activates ERK and AKT kinases in cancer cells via LHCGR-independent mechanism.

Aleksandra Głodek1, Anna Jankowska.   

Abstract

Expression of human chorionic gonadotropin free beta subunit (hCGβ) and its hyperglycosylated variant (hCGβ-H) is a phenomenon confirmed for tumors of different origin. Despite numerous studies, the mechanism of hCGβ action in cancer remains unknown especially that not all tumors secreting hCGβ express the receptor for human chorionic gonadotropin (LHCGR). In the presented study, we verified the hypothesis of hCGβ potential to activate signaling pathways involving extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) kinases with and without the contribution of LHCGR. To achieve this goal, human ovarian carcinoma cells OVCAR-3 expressing LHCGR and SKOV-3 not expressing LHCGR were either transfected with a vector coding for hCGβ or stimulated with recombinant hCGβ and the level of pERK and pAKT was measured. The results of the experiments showed that hCGβ action leads to the increase in ERK and AKT kinases phosphorylation in cancer cells and indicate that these biological effects can be achieved independently of LHCGR presence. The study also demonstrated that the presence of the receptor is a key factor influencing the magnitude of cells' response.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24554412     DOI: 10.1007/s13277-014-1715-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  48 in total

1.  Overexpression of the β subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis.

Authors:  Xiaoqing Guo; Guangzhi Liu; Isaiah G Schauer; Gong Yang; Imelda Mercado-Uribe; Fan Yang; Shiwu Zhang; Yuanli He; Jinsong Liu
Journal:  Am J Pathol       Date:  2011-07-18       Impact factor: 4.307

2.  Hyperglycosylated hCG, hCGβ and Hyperglycosylated hCGβ: interchangeable cancer promoters.

Authors:  Laurence A Cole; Stephen Butler
Journal:  Mol Cell Endocrinol       Date:  2011-11-12       Impact factor: 4.102

3.  Human chorionic gonadotropin β induces cell motility via ERK1/2 and MMP-2 activation in human glioblastoma U87MG cells.

Authors:  Zongwen Li; Lianlian Du; Chunliu Li; Wei Wu
Journal:  J Neurooncol       Date:  2012-12-13       Impact factor: 4.130

4.  MA-10 cells transfected with the human lutropin/choriogonadotropin receptor (hLHR): a novel experimental paradigm to study the functional properties of the hLHR.

Authors:  Takashi Hirakawa; Colette Galet; Mario Ascoli
Journal:  Endocrinology       Date:  2002-03       Impact factor: 4.736

5.  Expression of beta-subunit of HCG genes during normal and failed pregnancy.

Authors:  Kristiina Rull; Maris Laan
Journal:  Hum Reprod       Date:  2005-08-25       Impact factor: 6.918

Review 6.  Immunological approaches against human chorionic gonadotropin for control of fertility and therapy of advanced-stage cancers expressing hCG/subunits.

Authors:  Gursaran P Talwar; Jagdish C Gupta; Neha V Shankar
Journal:  Am J Reprod Immunol       Date:  2011-04-19       Impact factor: 3.886

7.  Ultrasensitive immunoradiometric assay for chorionic gonadotropin which does not cross-react with luteinizing hormone nor free beta chain of hCG and which detects hCG in blood of non-pregnant humans.

Authors:  J Griffin; W D Odell
Journal:  J Immunol Methods       Date:  1987-11-05       Impact factor: 2.303

8.  Evidence that human chorionic gonadotropin/luteinizing hormone receptor down-regulation involves decreased levels of receptor messenger ribonucleic acid.

Authors:  Y M Hoffman; H Peegel; M J Sprock; Q Y Zhang; K M Menon
Journal:  Endocrinology       Date:  1991-01       Impact factor: 4.736

9.  LH(hCG) receptor in benign and malignant tumors of human ovary.

Authors:  H Rajaniemi; A Kauppila; L Rönnberg; K Selander; P Pystynen
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1981

10.  Human chorionic gonadotropin β induces migration and invasion via activating ERK1/2 and MMP-2 in human prostate cancer DU145 cells.

Authors:  Zongwen Li; Chunliu Li; Lianlian Du; Yan Zhou; Wei Wu
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more
  2 in total

1.  Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.

Authors:  Anna Klimaszewska-Wiśniewska; Marta Hałas-Wiśniewska; Alina Grzanka; Dariusz Grzanka
Journal:  Int J Mol Sci       Date:  2018-02-27       Impact factor: 5.923

Review 2.  Unconventional Actions of Glycoprotein Hormone Subunits: A Comprehensive Review.

Authors:  Bruno Querat
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-21       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.